Raymond James raised the firm’s price target on Boston Scientific to $85 from $73 and keeps a Strong Buy rating on the shares. Boston Scientific was strong where it needed to be strong and exceeded a high bar on nearly every metric, the analyst tells investors in a research note. With a consistent double-digit top/bottom line growth profile, Raymond James expects Boston Scientific to be one of the fastest growing large cap healthcare names.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific sees FY24 adjusted EPS $2.29-$2.34, consensus $2.25
- Boston Scientific sees Q2 adjusted EPS 57c-59c, consensus 56c
- Boston Scientific reports Q1 adjusted EPS 56c, consensus 51c
- Boston Scientific Announces Results for First Quarter 2024
- Notable companies reporting before tomorrow’s open
